Mark Parry-Billings – Biography
Last update: April 1, 2026Executive profile
Mark was Head, Drug Development at Chiesi Group, and Chief Executive Officer at Topigen Pharmaceuticals. Mark Parry-Billings joined Synairgen in 2024.
Mark Parry-Billings is currentlyChairman of the Board at Synairgen - View - Synairgen org chart
Create your alert
to follow the career of Mark Parry-Billings.
Education
Mark Parry-Billings has a Post-Doctoral Fellowship in Clinical Biochemistry from University of Oxford.
They have also studied at University of Oxford :
Find more alumni from University of Oxford
More about Mark Parry-Billings
Selected links
Do you need to know more about Mark Parry-Billings? More results.
Participate
Social media
- Mark Parry-Billings on Google News, X (Twitter), LinkedIn, YouTube
- View the pictures of Mark Parry-Billings
The colleagues of Mark Parry-Billings
Company Colleagues
- At Synairgen, Mark Parry-Billings has 8 colleagues including Joseph Colliver (CEO & CFO), John Bradshaw (Director)…
Industry Colleagues
- In the Biotechnology industry, Mark Parry-Billings has 35,756 colleagues in 2,406 companies located in 42 countries. 16,877 executive movements have been recorded in the last 12 months. Learn more about Biotechnology.
Report an error
Update the org chart details of Mark Parry-Billings.
Get in Touch
Here are a few tips for establishing great contacts.
